Oral cavity cancers treated with superselective intra-arterial chemoradiotherapy with radiation doses less than 60 Gy: implications for dose reduction from a propensity score-matched analysis

Q4 Health Professions
H. Kaizu, M. Hata, K. Mitsudo, Y. Hayashi, E. Ito, M. Sugiura, S. Takano, Y. Mukai, I. Koike, T. Koizumi
{"title":"Oral cavity cancers treated with superselective intra-arterial chemoradiotherapy with radiation doses less than 60 Gy: implications for dose reduction from a propensity score-matched analysis","authors":"H. Kaizu, M. Hata, K. Mitsudo, Y. Hayashi, E. Ito, M. Sugiura, S. Takano, Y. Mukai, I. Koike, T. Koizumi","doi":"10.18869/ACADPUB.IJRR.18.3.531","DOIUrl":null,"url":null,"abstract":"Background: The optimal radiation dose for oral cavity cancers treated with retrograde superselective intra-arterial chemoradiotherapy (SIACRT) is unclear. The aim of the present study was to evaluate the treatment outcome and toxicity in patients treated with <60 Gy compared with those treated with ≥60 Gy to provide evidence for determining the optimal dose. Materials and Methods: Between January 2009 and December 2013, 159 oral cavity cancer patients were treated with SIACRT with curative intent at a single institution. One hundred and twenty-nine patients received ≥60 Gy and 30 received <60 Gy. Local control (LC), disease-free survival (DFS), overall survival (OS), and toxicity were compared. Propensity score matching was performed to reduce bias. Results: The median follow-up period was 48 months (range, 2–88 months). LC (<60 Gy vs. ≥60 Gy, 81.5% vs. 86.1% at 3 years, p = 0.534), DFS (68.8% vs. 72.4% at 3 years, p = 0.816), and OS (85.9% vs. 72.3% at 3 years, p = 0.132) were comparable between the two groups. There was also no difference in toxicity. However, the median overall treatment period was significantly shorter in the <60 Gy cohort (39 days vs. 49 days, p < 0.0001). Conclusion: The radiation dose may be reduced to <60 Gy when treating oral cavity cancers with SIACRT.","PeriodicalId":14498,"journal":{"name":"Iranian Journal of Radiation Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Radiation Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18869/ACADPUB.IJRR.18.3.531","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Health Professions","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The optimal radiation dose for oral cavity cancers treated with retrograde superselective intra-arterial chemoradiotherapy (SIACRT) is unclear. The aim of the present study was to evaluate the treatment outcome and toxicity in patients treated with <60 Gy compared with those treated with ≥60 Gy to provide evidence for determining the optimal dose. Materials and Methods: Between January 2009 and December 2013, 159 oral cavity cancer patients were treated with SIACRT with curative intent at a single institution. One hundred and twenty-nine patients received ≥60 Gy and 30 received <60 Gy. Local control (LC), disease-free survival (DFS), overall survival (OS), and toxicity were compared. Propensity score matching was performed to reduce bias. Results: The median follow-up period was 48 months (range, 2–88 months). LC (<60 Gy vs. ≥60 Gy, 81.5% vs. 86.1% at 3 years, p = 0.534), DFS (68.8% vs. 72.4% at 3 years, p = 0.816), and OS (85.9% vs. 72.3% at 3 years, p = 0.132) were comparable between the two groups. There was also no difference in toxicity. However, the median overall treatment period was significantly shorter in the <60 Gy cohort (39 days vs. 49 days, p < 0.0001). Conclusion: The radiation dose may be reduced to <60 Gy when treating oral cavity cancers with SIACRT.
放射剂量小于60Gy的超选择性动脉内放化疗治疗口腔癌:倾向评分匹配分析对剂量减少的影响
背景:逆行超选择性动脉内放化疗(SIACRT)治疗口腔癌的最佳放射剂量尚不清楚。本研究的目的是评估<60Gy与≥60Gy治疗患者的治疗结果和毒性,为确定最佳剂量提供证据。材料和方法:2009年1月至2013年12月,159例癌症口腔患者在一家机构接受了SIACRT治疗。129名患者接受≥60 Gy治疗,30名患者接受<60 Gy。比较局部控制(LC)、无病生存期(DFS)、总生存期(OS)和毒性。进行倾向性评分匹配以减少偏差。结果:中位随访期为48个月(范围为2-88个月)。LC(<60 Gy vs.≥60 Gy,81.5%vs.86.1%,3年,p=0.534)、DFS(68.8%vs.72.4%,3年时,p=0.816)和OS(85.9%vs.72.3%,3年后,p=0.132)在两组之间具有可比性。毒性也没有差异。然而,<60Gy队列的中位总治疗期明显更短(39天vs.49天,p<0.0001)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Iranian Journal of Radiation Research
Iranian Journal of Radiation Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
CiteScore
0.67
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: Iranian Journal of Radiation Research (IJRR) publishes original scientific research and clinical investigations related to radiation oncology, radiation biology, and Medical and health physics. The clinical studies submitted for publication include experimental studies of combined modality treatment, especially chemoradiotherapy approaches, and relevant innovations in hyperthermia, brachytherapy, high LET irradiation, nuclear medicine, dosimetry, tumor imaging, radiation treatment planning, radiosensitizers, and radioprotectors. All manuscripts must pass stringent peer-review and only papers that are rated of high scientific quality are accepted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信